Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Angelica, Michelini"'
Autor:
Nicola Personeni, Laura Giordano, Angelica Michelini, Antonio D’Alessio, Antonella Cammarota, Silvia Bozzarelli, Tiziana Pressiani, Maria Giuseppina Prete, Maria Teresa Sandri, Sabine Stioui, Luca Germagnoli, Armando Santoro, Lorenza Rimassa, Rossana Mineri
Publikováno v:
Journal of Personalized Medicine; Volume 12; Issue 2; Pages: 204
Current guidelines recommend pre-therapeutic UGT1A1 genotyping to guide irinotecan dosing, but the usefulness of this approach remains to be clarified. In 247 patients with advanced gastrointestinal cancers undergoing irinotecan-based chemotherapy, w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b988b9fa4b1d3eab16d08d273fe9888
Autor:
Nicola, Personeni, Laura, Giordano, Angelica, Michelini, Antonio, D'Alessio, Antonella, Cammarota, Silvia, Bozzarelli, Tiziana, Pressiani, Maria Giuseppina, Prete, Maria Teresa, Sandri, Sabine, Stioui, Luca, Germagnoli, Armando, Santoro, Lorenza, Rimassa, Rossana, Mineri
Publikováno v:
Journal of personalized medicine. 12(2)
Current guidelines recommend pre-therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::eae526498b752cc6aee9c67ed63f90da
https://pubmed.ncbi.nlm.nih.gov/35207692
https://pubmed.ncbi.nlm.nih.gov/35207692
Autor:
Tiziana Pressiani, Maria Teresa Sandri, Lorenza Rimassa, Silvia Bozzarelli, Armando Santoro, Rossana Mineri, Nicola Personeni, Angelica Michelini, Laura Giordano, Valeria Smiroldo
Publikováno v:
Web of Science
e16116 Background: IRI is widely used in the treatment of gastrointestinal cancers. Consistent with current guidelines, UGT1A1 genotyping may drive IRI dose reductions, but the usefulness of this approach is still unclear. We assessed potential clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18835c93c0bbda94b790642486933d51
https://publons.com/wos-op/publon/43042831/
https://publons.com/wos-op/publon/43042831/
